PDSB - PDS Biotechnology up 3% after reporting data on triple combination for HPV cancers

• PDS Biotechnology ( NASDAQ: PDSB ) is up 3% in premarket trading on results on the company's triple combination therapy for human papillomavirus (HPV)-positive cancers.
• The triple combination includes the company's PDS0101, the tumor-targeting IL-12 fusion protein M9241, and bintrafusp alfa.
• All participants had failed on chemo and 90% had failed on radiation treatment.
• Results showed that out of 29 patients who failed on checkpoint inhibitors, the median overall survival ( OS ) was 21. months. The historical median OS in patients in this group is three to four months.
• The objective response rate (ORR) in checkpoint inhibitor ("CPI") naïve patients with the triple combination was 88%. The ORR is reported to be less than 25% with CPIs in HPV-associated cancers.
• Read why BioSci Capital Partners views PDS Biotechnology ( PDSB ) as a buy.

For further details see: